A Retrospective, Multicenter and Observational Study of Osimertinib Monotherapy Treatment in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive Who Have Received the Treatment Within the Special Use Medication Program in Spain
Latest Information Update: 06 Jun 2022
At a glance
- Drugs Osimertinib (Primary) ; Erlotinib; Gefitinib
- Indications Adenocarcinoma; Cancer metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms OSIREX
Most Recent Events
- 31 Jan 2021 Results (n=155) of response analysis presented at the 2020 World Conference on Lung Cancer
- 07 Apr 2020 Status changed from active, no longer recruiting to completed.
- 08 Jan 2020 Planned End Date changed from 15 Dec 2019 to 15 Mar 2020.